← Back to Clinical Trials
Recruiting Phase 4 NCT03717623
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Trial Parameters
Condition Posaconazole
Sponsor Melbourne Health
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-08-01
Completion 2025-12-30
All Conditions
Interventions
Posaconazole pharmacokinetics
Brief Summary
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
Eligibility Criteria
Inclusion Criteria: * Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care. * Able to give informed consent. Exclusion Criteria: * Unable to give informed consent.